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The tumour suppressor p53 is a transcription factor with powerful antitumour activity that is controlled by its negative regulator
MDM2 (mouse double minute 2, also termed HDM2 in humans) through a feedback mechanism. MDM2, which is overproduced in
many tumours, binds p53 and inhibits its function by modulating its transcriptional activity and stability. Activation of p53 in tumour
cells by inhibiting its physical interaction with MDM2 has been in the focus of cancer drug discovery. However, development of
nonpeptidic MDM2 antagonists turned out to be challenging. Recently, the first potent and selective small-molecule antagonists of
MDM2, the Nutlins, have been identified. Studies with Nutlins provided in vitro and in vivo proof-of-principle for targeting p53–MDM2
interaction for cancer therapy.
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Since the discovery of its powerful growth suppressive and
proapoptotic activity, the tumour suppressor p53 has been in the
centre of attention of drug hunters. The idea of unleashing the
destructive powers of p53 inside cancer cells has become even
more attractive after the realisation that p53 is controlled largely
by a single master regulator, MDM2, which binds the tumour
suppressor and negatively modulates its activity and stability.
Therefore, MDM2 antagonists able to release p53 from the
inhibitory grip of MDM2 are expected to stabilise and activate
the tumour suppressor, leading to cell cycle arrest or programmed
cell death (apoptosis) of cancer cells. Such antagonists could
represent a novel modality to treat tumours in which p53 has
retained its wild-type structure and function.
Targeting the physical interaction between p53 and MDM2 has
been regarded as the most direct of all p53-activating strategies.
However, protein–protein interactions have long been viewed as
high-risk targets due to the fact that proteins generally offer
relatively large and flat interacting surfaces that are not readily
disturbed by small-molecule drugs (Arkin and Wells, 2004). This
view has been challenged during the recent years by several proof-
of-concept studies that targeted protein interactions with pepti-
domimetic and small-molecule antagonists (Toogood, 2002; Arkin
and Wells, 2004). Most of these compounds, however, have
exhibited low potency and/or inadequate pharmacological proper-
ties and the development of small-molecule protein–protein
therapeutics is still in its infancy.
The strong interest in targeting the p53–MDM2 interaction has
led to the identification of several macromolecular tools that
helped to validate the principle of this p53-activating approach.
However, the discovery of pharmacologically relevant small-
molecule inhibitors of p53–MDM2 binding turned out to be more
challenging than initially thought. Nevertheless, progress in this
direction has been made and recently the first potent and selective
low-molecular-weight nonpeptidic MDM2 antagonists have been
identified. This minireview focuses on the p53-MDM2 interaction
as a target for discovery of novel cancer therapeutics.
Cellular roles of p53 and mdm2
The tumour suppressor p53 plays a pivotal role in protection
from cancer development that may arise from diverse forms of
cellular stress (Levine, 1997; Vogelstein et al, 2000; Vousden and Lu,
2002). p53 is a potent transcription factor, which is activated
following stress and regulates multiple downstream genes implicated
in cell cycle control, apoptosis, antiangiogenesis and senescence.
Owing to its central role as a cellular gatekeeper, the p53 pathway
is the most frequent target of genetic alterations in cancer.
Approximately half of all human tumours express p53 that is
disabled by mutations in its DNA-binding domain and is thus
inactive as a transcription factor (Hainaut and Hollstein, 2000). In
addition, p53 can be inactivated by binding to viral proteins such as
the E6 protein of papilloma viruses (Levine, 1997). Growth
suppressive and proapoptotic activity of p53 could harm proliferat-
ing cells that are not under stress. Therefore, the level of p53 in
these cells is a subject of tight control. This important role is played
by the p53 regulator MDM2 (mouse double minute 2, also termed
HDM2 in humans).
MDM2 was originally identified as an oncoprotein that binds to
p53 and inhibits p53-mediated transactivation (Momand et al,
2000). The mdm2 gene was found to be upregulated in human
tumours and tumour cell lines by gene amplification, increased
transcript levels and enhanced translation. The overall frequency
of MDM2 amplification in human tumour tissue samples is
approximately 7% with the highest frequency observed in soft-
tissue sarcomas (20–30%), osteosarcomas (16%) and oesophageal
carcinomas (13%). Simultaneous mutation of p53 and amplifica-
tion of MDM2 does not generally occur within the same tumour,
suggesting that MDM2 amplification is an effective means for
inactivation of p53 function (Momand et al, 1998).
The mdm2 gene encodes a protein consisting of several
domains: (i) N-terminal domain that contains the binding sites
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ARF; (iii) putative Zn-finger and binding
site for the retinoblastoma protein Rb; and (iv) a RING-finger and
E3 ligase domain that is responsible for the ubiquitination of p53.
In addition, MDM2 contains nuclear import and export sequences
(Momand et al, 2000).
The main cellular function of MDM2 is to regulate p53 levels.
This is strongly supported by the observation that embryonic
lethality of mdm2-null mice can be reversed only by the
simultaneous deletion of the p53 gene (Jones et al, 1995; Monies
de Oca Luna et al, 1995). MDM2 regulates p53 through an
autoregulatory feedback loop. When nuclear p53 level is elevated,
it activates the transcription of the mdm2 gene, thus raising the
level of MDM2 protein. In turn, MDM2 binds to p53, which (a)
blocks its N-terminal transactivation domain and (b) targets p53
for degradation via the ubiquitin–proteasome system following
ubiquitinylation through its E3 ligase activity. Both p53 and MDM2
have a short half-life and their nuclear concentrations are kept at
very low levels as a result of the proper functioning of the
regulatory circuit (Freedman et al, 1999; Juven-Gershon and Oren,
1999). However, in cancers overexpressing MDM2 this feedback
loop is dysregulated. Stress-induced p53 activation mechanisms in
these tumours are believed to be inadequate, leading to inefficient
growth arrest and/or apoptosis. Therefore, blocking the p53–
MDM2 interaction is expected to overcome the oncogenic
consequences of MDM2 overproduction and to restore p53
function. Treatment of cancer cells with MDM2 antagonists
should result in the concurrent transcriptional activation of p53
downstream genes followed by the induction of cell cycle arrest
and apoptosis.
The p53–MDM2 interaction
Genetic and biochemical studies mapped the p53–MDM2 inter-
action sites to the N-terminal domain of MDM2 and the N-
terminal part of the transactivation domain of p53 also termed
BOX1 domain (Chen et al, 1993; Picksley et al, 1994). Crystal
structures of the N-terminal domains of human and Xenopus laevis
MDM2 in complex with short peptides from the N-terminal
domain of p53 (residues 15–29) revealed the structural basis of the
interaction between p53 and MDM2 (Kussie et al, 1996). Upon
binding to MDM2, the unstructured p53 transactivation domain
(Lee et al, 2000; Dawson et al, 2003) forms an amphiphilic a-helix
that projects the hydrophobic residues of Phe
19, Trp
23 and Leu
26
into a deep hydrophobic binding pocket on the MDM2 surface
(Kussie et al, 1996; Blommers et al, 1997). The p53 structural
changes induced by MDM2 provide an explanation for how
MDM2 binding inhibits the transcriptional activity of p53. Mouse
double minute 2 binding site on p53 coincides with the a-helical
FxxFF-motif (F: phenylalanine; F: hydrophobic residue; in p53:
Trp
23) that is responsible for binding of important components
of the transcription machinery such as hTAFII31 (Uesugi and
Verdine, 1999).
Searching for novel peptides that can bind MDM2, Bottger et al
have identified the IPS peptide displaying a 30-fold higher affinity
than the native p53 peptide (17–29) (Bottger et al, 1996). This
peptide contained several additional hydrophobic residues. Align-
ment of the peptide sequences derived from phage display allowed
the definition of a consensus motif for binding to MDM2
(PxFxDYWxxL) (Bottger et al, 1996; Bottger et al, 1997a).
Combinatorial permutation and biophysical studies using syn-
thetic peptides have revealed the main structural requirements for
binding to MDM2 (Schon et al, 2004). These experimental data
together with rationalisation on the basis of the crystal structure of
p53–MDM2 interaction (Kussie et al, 1996) have allowed to
develop a quantitative structure–activity relationship (QSAR) that
might help in the identification of small-molecule MDM2
antagonists (Galatin and Abraham, 2001).
Using a semirational drug design and NMR spectroscopy,
Garcia-Echeverria et al (2000) generated a highly potent peptidic
MDM2 antagonist termed AP peptide (19–26). The affinity of the
AP peptide has been enhanced by the introduction of artificial
amino acids in the minimal sequence derived from the IP3 peptide.
These residues have stabilised entopically the helical conformation
of the peptide and formed additional polar and hydrophobic van
der Waals interactions with MDM2. This optimisation improved
the affinity of the AP peptide to MDM2 by 60-fold in comparison
with IP3 and almost 2000-fold in comparison with the native p53
peptide (Garcia-Echeverria et al, 2000). Recently, cyclic peptido-
mimetic inhibitors of MDM2 have been described that mimic the
a-helix by b-hairpins (Fasan et al, 2004).
Validation of the p53–MDM2 interaction as a drug target
The realisation that p53–MDM2 binding involves the interaction
of three critical amino-acid residues from p53 with a well-defined
hydrophobic pocket on the surface of MDM2 have raised the hope
that identifying pharmacological inhibitors of this interaction
might be possible. Several different approaches have been used to
validate p53–MDM2 interaction as a drug target. These include: (i)
microinjection of monoclonal antibodies directed against the
p53 binding site on MDM2 (Blaydes et al, 1997; Bottger et al,
1997b); (ii) inhibition of MDM2 expression by antisense oligonu-
cleotides (Chen et al, 1999; Wang et al, 1999, 2001; Geiger et al,
2000; Zhang et al, 2003); (iii) microinjection or intracellular
expression of short fusion proteins (Bottger et al, 1997b; Wasylyk
et al, 1999); and (iv) transduction of cells with IP3 and AP peptides
coupled to peptide transduction domains (e.g. penetratin and Tat)
(Chene et al, 2000, 2002; Garcia-Echeverria et al, 2001).
Collectively, these studies have demonstrated that blocking the
p53–MDM2 binding can disrupt the p53 regulatory circuit, leading
to p53 accumulation and activation of the p53 pathway. However,
most of the studies have used macromolecular tools (proteins or
peptides) with limited applicability to studies in living cells or
animal models of cancer. One notable exception is the antisense
approach. Several antisense studies have demonstrated that
phosphorothioate oligonucleotides directed against MDM2 can
suppress MDM2 expression effectively, thus leading to the
accumulation of p53 and activation of the p53 pathway. The
consequences of p53 activation have been examined in several
mouse xenograft models of human cancer. They have shown the
anticipated tumour growth suppression that is enhanced by
combination with established genotoxic drugs (Zhang et al,
2003). Surprisingly, in all antisense studies the antitumour effect
was not limited to cancer cells with wild-type p53 as expected
from disruption of the p53–MDM2 regulatory loop. Instead,
antisense treatment affected equally well cells in which p53 is
disabled by mutation. These observations have complicated the
interpretation of the antisense results. However, a recent finding
from the same group that MDM2 can bind the cyclin-dependent
kinase inhibitor p21
waf1/cip1 and inhibit its activity have shed a new
light on the role of MDM2 and the consequences of MDM2
inhibition (Zhang et al, 2004).
An important aspect in the validation of the p53–MDM2
interaction as a cancer target is assessing the consequences of p53
activation in the normal proliferating tissues. It has been shown
that activation of the p53 pathway can lead to toxicity in tissues
with relatively high proliferative index. This toxicity could arise
from both main functions of p53: cell cycle arrest and apoptosis,
and could narrow the therapeutic window of any p53-activating
therapy. Indeed, MDM2-null mouse embryos die at day 5.5 most
likely due to apoptosis in the rapidly proliferating tissues (de
Rozieres et al, 2000). However, recent studies both in vitro and in
vivo have suggested that the consequences of p53 activation in
cancer and normal cells may differ. Activation of the p53 pathway
in human fibroblasts has been shown to elicit growth arrest when
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et al, 1999). Studies with conditional MDM2 knockouts provide in
vivo evidence for the rationale of inhibiting the p53–MDM2
interaction for the treatment of cancer (Mendrysa et al, 2003).
According to these studies, inhibition of MDM2 does not cause
major target-related toxicity with the possible exception of certain
mild haematopoietic abnormalities. Moreover, they imply that
even partial inhibition of MDM2 is sufficient to activate the p53
pathway in vivo and/or synergise with radiation or cytotoxic
therapeutics. Genetic modulation of MDM2 levels in mice also
suggests that p53 regulation during homeostasis may differ from
its regulation in cancer tissues (O’Leary et al, 2004).
Pharmacological inhibitors of the p53–MDM2 interaction
In this section, we will review the efforts on developing direct
protein–protein binding antagonists of MDM2. For an example of
targeting the E3 ubiquitin ligase activity of MDM2 see Lai et al
(2002). The first reported small-molecule MDM2 antagonists,
the chalcones, are derivatives of phenoxy acetic acid and
phenoxymethyl tetrazole (Figure 1A). Chalcones have been
shown to inhibit p53–MDM2 interaction with IC50 values in the
high mM range by binding to the p53 pocket on MDM2 as
revealed by NMR spectroscopy. However, in addition to their low
potency they have shown other liabilities such as inhibition of
glutathione-S-transferase activity that have limited severely
their use (di Domenico et al, 1999; Stoll et al, 2001). Recently,
novel boronic–chalcone derivatives have been described as
putative MDM2 antagonists with antitumour effect against
cultured tumour cells (Kumar et al, 2003). Whether or not
these compounds exert their antitumour effect solely via inhibition
of the p53–MDM2 interaction still needs to be demonstrated
(Kumar et al, 2003).
Using computer-aided design, Zhao et al have synthesised
putative nonpeptidic polycyclic MDM2 antagonists. Their initial
evaluation has shown a moderate affinity for MDM2 and induction
of the p53 pathway in tumour cell lines (Zhao et al, 2002).
The fungal cyclic nonapeptide Chlorofusin (Figure 1C) was
identified by screening a library of microbial extracts. Chlorofusin
binds to MDM2 and inhibits the p53–MDM2 interaction. Owing
to the high KD value of 4.6mM, the complex chemical structure and
a high molecular mass Chlorofusin does not represent a
candidate drug but might serve as a lead structure for the
design of more potent analogues (Duncan et al, 2001, 2003).
Several small-molecule antagonist of MDM2 have appeared in
recently published patents. However, the limited functional data
provided does not allow evaluation of their significance as
novel MDM2 antagonists. In summary, the small-molecule
p53–MDM2 binding inhibitors described in the literature so far
have shown modest potency, lack of selectivity and inadequate
pharmacological properties.
Recently, we have identified the first potent and selective small-
molecule antagonists of the p53–MDM2 interaction, the Nutlins
(Vassilev et al, 2004). These cis-imidazoline derivatives bind tightly
into the p53 pocket of MDM2 and displace p53 from its complexes
with MDM2 in vitro with IC50 in the 100–300nM range. The crystal
structure of MDM2–Nutlin complexes revealed that Nutlins
project functional groups into the binding pocket that mimic to
a high degree the interaction of the three p53 amino acids critical
for the interaction: Phe
19, Trp
23 and Leu
26. Figure 2 shows the high
steric complementarity with which the Nutlins bind into the
hydrophobic p53-binding pocket on MDM2. Nutlins penetrated
cell membranes and inhibited p53–MDM2 binding, leading to
stabilisation of p53 and activation of p53 target genes (Stommel
and Wahl, 2004; Vassilev et al, 2004). The activation of the p53
pathway in cancer cells was manifested by cell cycle arrest in G1
and G2 phase and caspase-dependent apoptosis. Nutlins showed
remarkable selectivity for the p53–MDM2 interaction. Their
antitumour effect was observed only in cells with wild-type p53
but not in cells with mutant or deleted p53, suggesting that Nutlin
activity is derived from activation of the p53 pathway. Interest-
ingly, the occupation of the p53-binding pocket on MDM2 by the
Nutlins appears sufficient to disrupt the complex of full-length p53
and MDM2 in vitro and in vivo independent of the recently
suggested additional interaction site between the two proteins
(Shimizu et al, 2002). Pharmacological properties of the Nutlins
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Figure 1 Small-molecule inhibitors of p53–MDM2 binding. (A) Chalcone, (B) boronic–chalcone, (C) Chlorofusin, and (D) Nutlin-2.
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mouse plasma through the desirable oral route of administration
and permitted us to perform proof-of-concept studies using mouse
xenograft models of human cancer. Treatment of established
human osteosarcoma xenografts (SJSA-1) with nontoxic doses of
Nutlin-3 for 3 weeks led to 90% inhibition of tumour growth
compared to vehicle controls. Since proliferating mouse fibroblasts
appear equally sensitive to MDM2 antagonists as cultured human
cells, lack of apparent toxicity during the course of treatment
suggests that normal and cancer cells may have different
tolerability to elevated level of p53 (Vassilev, 2004). Additional
studies with histopathological examination of multiple mouse
tissues are needed to assess the potential side effects of this p53-
activating approach.
CONCLUSIONS
The interaction between the master tumour suppressor p53 and its
negative regulator MDM2 has been in the focus of cancer drug
discovery for nearly a decade. Multiple studies have validated the
concept that disrupting this protein–protein interaction can
activate the p53 pathway in cancer cells. The identification of the
first potent and selective small-molecule MDM2 antagonists,
the Nutlins, made it possible to perform in vivo validation studies
and strengthen the notion that targeting the p53–MDM2
interaction can provide a potentially viable strategy for treating
cancer. However, many questions need to be answered before we
can understand the true utility of MDM2 antagonists in cancer
therapy. Although as many as 50% of all human tumours
have retained wild-type p53, and should be thus sensitive to
p53-activating therapy, the response rate will most likely be
limited by defects in the p53 pathway downstream of p53. Our
current state of knowledge points to tumours with wild-type p53
and MDM2 gene amplification as the most likely responders of
therapy with MDM2 antagonists. It is believed that in these
tumours MDM2 overexpression is the only aberration, thus
the restoration of p53 function should lead to an effective
apoptotic response. Preclinical studies, now in progress, are aimed
at addressing the role of MDM2 status and the genetic background
of other members of the p53 pathway in the response to p53
activation by Nutlins.
In summary, the discovery of Nutlins as potent MDM2
antagonists with in vitro an in vivo activity have provided
compelling evidence that the p53–MDM2 interaction represents
a tractable target for pharmacological intervention. Given the
plethora of data supporting the therapeutic concept of p53
activation, there seems to be a realistic chance that the quest for
small-molecule MDM2 antagonists can translate into a clinical
benefit in the near future.
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